Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Evotec SENASDAQ: EVO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -€97.35M, compared with -€27.44M a year earlier. Trailing-twelve-month EBITDA was -€95.93M.
Context
- EBITDA amounted to 1.8% of revenue in FY2025, down 8.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -€141.95M (-921.8%) for the fiscal year ending Dec 2026, a slowdown from the +82.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€97.35M-272.3% QoQ
- Last fiscal yearDec 2025
- -€13.89M+82.8% YoY
- LTMMar 2026
- -€95.93M-47.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -254.7% | +141.3% | +396.0 pp |
| 1 year | +82.8% | -921.8% | -1004.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- (13.89M) EUR
- Year-over-year change
- +82.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.89M) | +82.8% |
| FY2024 | 2024-12-31 | (80.66M) | -434.3% |
| FY2023 | 2023-12-31 | 24.13M | +141.9% |
| FY2022 | 2022-12-31 | (57.61M) | -118.2% |
| FY2021 | 2021-12-31 | 316.63M | — |
EBITDA vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -47.8% is the 6th highest of 11, against a peer median of -39.1%.
- EBITDA amounts to 12.9% of revenue for EVO, versus a peer median of 15.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $118.4M USD | +322.5% | -4.4% | 16.1% | |
| LTM Mar 2026 | $57.31M USD | +74.6% | — | 2.3% | |
| LTM Mar 2026 | $51.83M USD | -62.7% | — | 9.3% | |
| LTM Mar 2026 | $31.47M USD | +78.4% | — | 11.7% | |
| LTM Sep 2026 | -$41.03M USD | +75.6% | — | 15.2% | |
| LTM Sep 2026 | -$94.49M USD | -265.1% | — | 15.2% | |
| LTM Mar 2026 | -€95.93M EUR | -47.8% | — | 12.9% | |
| LTM Mar 2026 | -$155.38M USD | -103.1% | — | 23.0% | |
| LTM Sep 2026 | -€184.94M EUR | -15.5% | — | — | |
| LTM Sep 2026 | -$280.09M USD | -70.6% | — | 309.5% | |
| LTM Feb 2026 | -$1.84B USD | -65.1% | — | 155.9% | |
| Peer median (excluding EVO) | — | -39.1% | -4.4% | 15.2% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 618.03M | 751.45M | 781.43M | 796.97M | 757.26M |
| Cost of Revenue | 466.49M | 577.38M | 606.38M | 682.09M | 694.6M |
| Gross Profit | 151.54M | 174.07M | 175.05M | 114.88M | 62.66M |
| Gross Margin | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| Research & Development | 65.7M | 76.64M | 68.53M | 50.86M | 74.33M |
| Selling, General & Admin | 105.45M | 156.19M | 169.61M | 188.2M | 123.65M |
| Operating Expenses | 110.55M | 153.22M | 222.56M | 257.4M | 197.97M |
| Depreciation & Amortization | 70.4M | 83.2M | 92.98M | 101.62M | 95.55M |
| EBITDA | 316.63M | (57.61M) | 24.13M | (80.66M) | (13.89M) |
| EBITDA Margin | 51.2% | -7.7% | 3.1% | -10.1% | -1.8% |
| Operating Income | 41M | 20.85M | (47.51M) | (142.52M) | (135.31M) |
| Operating Margin | 6.6% | 2.8% | -6.1% | -17.9% | -17.9% |
| Interest Income | 2.27M | 8.34M | 9.26M | 2.44M | 4.25M |
| Interest Expense | 9.25M | 13.15M | 11.74M | 11.7M | 13.87M |
| Other Income / Expenses | 195.98M | (174.81M) | (33.09M) | (51.46M) | 12M |
| Income Before Tax | 236.98M | (153.96M) | (80.59M) | (193.98M) | (123.31M) |
| Pre-Tax Margin | 38.3% | -20.5% | -10.3% | -24.3% | -16.3% |
| Income Tax Expense | 21.47M | 21.7M | 3.32M | 2.1M | (23.88M) |
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Net Margin | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (Basic) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| EPS (Diluted) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| Weighted Avg Shares | 332.81M | 353.35M | 353.87M | 353.29M | 355.16M |
| Weighted Avg Shares (Diluted) | 332.81M | 353.41M | 353.87M | 354.59M | 355.16M |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.